All sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc. $4578.T

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS17
PHASE 3 / 2-312
RECRUITING8
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO33%

Delay Index: of 9 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Otsuka Pharmaceutical Development & Commercialization, Inc. on the live radar map → 📅 $4578.T readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Sibeprenlimab 400 mg
NCT05248646
P3Active, not recruitingImmunoglobulin A Nephropathy5302026-05-13 (-8 mo)
SEP-363856
NCT06894212
P3Active, not recruitingSchizophrenia5382026-10-20 (-18 mo)
EnVISage
NCT06928142
P2Active, not recruitingSjogren Disease832027-03-13
Centanafadine XR
NCT07759154
P3RecruitingAttention-deficit/Hyperactivity Disorder; Emotional Dysregulation802027-05-27
JNT-517
NCT06628128
P3RecruitingPhenylketonuria (PKU)2402027-11-01
JNT-517
NCT06971731
P3RecruitingPhenylketonuria1202028-03-01 (+16 mo)
Sibeprenlimab
NCT07861113
P2Not yet recruitingPrimary Membranous Nephropathy; Minimal Change Disease202028-06-15
QUANTUM-TB
NCT07209761
P3RecruitingRifampicin-Resistant Pulmonary Tuberculosis; Multidrug-Resistant Pulmonary Tuberculosis5322028-09-29 (+16 mo)
SEP-363856
NCT07767903
P3RecruitingGeneralized Anxiety Disorder3842028-10-25
SEP-363856
NCT07759128
P3RecruitingGeneralized Anxiety Disorder5762028-12-06
Sibeprenlimab
NCT06740526
P2Active, not recruitingIgA Nephropathy562028-12-28 (-4 mo)
Sibeprenlimab 400 mg s.c. Q4weeks
NCT05248659
P2/3Enrolling by invitationImmunoglobulin A Nephropathy6002028-12-28
Tolvaptan Suspension
NCT04782258
P3RecruitingAutosomal Recessive Polycystic Kidney (ARPKD)202028-12-28 (+45 mo)
VIS954
NCT07933445
P2Not yet recruitingInflammatory Skin Diseases1082029-03-13
SEP-363856
NCT07786454
P3RecruitingGeneralized Anxiety Disorder11202029-05-26
VIS954
NCT07904806
P2Not yet recruitingAntineutrophil Cytoplasmic Antibody-associated Vasculitis752029-11-20
Sibeprenlimab
NCT07770815
P3Not yet recruitingIgA Nephropathy242029-12-29